Dengue Literature Review

Lin2001 - IgM Anti-Platelet Autoantibody in Dengue Patients

7 min read

Lin2001 - IgM Anti-Platelet Autoantibody in Dengue Patients

Full citation: Lin CF, Lei HY, Liu CC, Liu HS, Yeh TM, Wang ST, Yang TI, Sheu FC, Kuo CF, Lin YS. Generation of IgM Anti-Platelet Autoantibody in Dengue Patients. J Med Virol. 2001;63(2):143–149. https://doi.org/10.1002/1096-9071(20000201)63:2<143::aid-jmv1009>3.0.co;2-l

Raw file: [[raw/lin2001.pdf]]

Summary

This is the foundational paper from the NCKU group (Tainan, Taiwan) establishing that dengue patient sera contain IgM-class autoantibodies that cross-react with human platelets. It predates the mechanistically more detailed Lin2006 - Autoimmune Pathogenesis in Dengue Virus Infection and Lin2011 - Molecular Mimicry Virus Host Dengue Pathogenesis from the same group, and is the original source for three claims those later papers assume or build upon: (1) anti-platelet autoantibodies are IgM not IgG; (2) anti-platelet IgM levels are higher in DHF/DSS than DF; (3) dengue sera cause complement-mediated platelet lysis. Importantly, Lin2001 also establishes two findings that subsequent papers do not emphasise: the distinction between platelet lysis (severity-correlated) and platelet aggregation inhibition (not severity-correlated); and the presence of anti-platelet IgM in the majority of patients with primary dengue infection — a direct challenge to the assumption that IgM anti-platelet production requires prior dengue exposure.

Patient sera came from the southern Taiwan DENV-3 outbreak of November 1998–January 1999, with three timepoints: acute (days 3–7), convalescent (1–3 weeks), and later (8–9 months). Four control virus groups (JEV, HCV, EV71, healthy normals) confirmed the dengue-specificity of the platelet-binding activity.

Study Design

  • Type: Experimental cohort with disease-stage comparisons; virus-infected control arms
  • Sample size: 5 dengue fever patients, 4 DHF/DSS patients (DENV-3); 1 dengue fever patient (DENV-2); 5 each for JEV, HCV, EV71 controls; 6 healthy controls
  • Setting: Southern Taiwan (NCKU Hospital, Tainan); DENV-3 outbreak November 1998–January 1999; DENV-3 confirmed and reported by Taiwan CDC
  • Population: Mixed paediatric/adult (ages 7–57); mostly male; primarily primary infection (majority confirmed by haemagglutination inhibition assay)

Key Findings

Anti-platelet autoantibodies are IgM, not IgG:

  • Flow cytometry with isotype-specific secondaries confirmed cross-reactive anti-platelet antibodies are exclusively IgM class; IgG anti-platelet antibodies were not detected in any dengue patient group
  • The absence of IgG is not due to lack of IgG production — high levels of anti-NS1 IgG were detected in these sera; the selectivity is epitope-specific

Anti-platelet IgM levels: DHF/DSS > DF (severity correlation):

  • Acute phase: DF 28.0±2.4% reactive platelets (MFI 140.0±15.5); DHF/DSS 34.6±4.1% (MFI 276.0±19.8) — both significantly above normal (normal: 6.5±1.3%, MFI 77.7±9.7); DHF/DSS significantly higher than DF (p<0.01)
  • Convalescent phase: DF 24.1±2.7% (MFI 101.0±4.0); DHF/DSS 26.3±3.8% (MFI 159.0±60.9)
  • Later stage (8–9 months): DF 15.7±4.9% (MFI 78.6±6.1); DHF/DSS 11.5±2.7% (MFI 95.3±13.3) — still detectable above normal, though DF MFI approaches normal range

Platelet lysis (complement-mediated): severity-correlated

  • Dengue patient sera cause platelet lysis in the presence of complement (measured by LDH release assay); lysis greatly amplified by complement vs. without complement
  • DHF/DSS sera caused higher lysis than DF sera
  • Dose-dependent relationship at serum dilutions from 1:25 to 1:200

Platelet aggregation inhibition: NOT severity-correlated ← critical nuance

  • Dengue patient sera inhibit ADP-induced platelet aggregation
  • DHF/DSS inhibition was NOT higher than DF inhibition — no severity correlation
  • Inhibitory activity was slightly higher at convalescence than acute phase — the opposite temporal pattern from platelet lysis and anti-platelet IgM binding
  • Conclusion by authors: aggregation inhibition does not contribute to severity differentiation between DF and DHF/DSS

Dengue-specificity confirmed:

  • JEV, HCV, and EV71 patient sera showed anti-platelet IgM levels identical to normal controls — platelet cross-reactivity is dengue-specific, not a generic viral infection feature
  • This is consistent with the immunodominant NS1-P1 epitope (aa 1–15) reacting with dengue but not JEV patient sera (Huang et al. 1999, cited)

Cross-serotype: DENV-2 patient:

  • One DENV-2 dengue fever patient (acute serum): 26.0±4.2% reactive platelets, MFI 132.5±18.5 — comparable to DENV-3 dengue fever acute values
  • Confirms the anti-platelet IgM phenomenon is not DENV-3-specific

Primary infection context — direct challenge to secondary-infection narrative:

  • Haemagglutination inhibition assay confirmed the majority of patients in this outbreak had primary infection, with only a few secondary
  • Yet DHF/DSS occurred, and anti-platelet IgM was present in both DF and DHF/DSS patients
  • Authors’ interpretation: Since anti-platelet autoantibodies are IgM class, their production is not associated with primary vs. secondary infection status. High anti-platelet IgM may explain why some primary infections cause DHF/DSS — providing an ADE-independent mechanism

NS1 as the source of cross-reactive epitopes (partially):

  • Unpublished data (cited) indicate anti-NS1 Abs partially account for platelet cross-reactivity
  • NS1 aa 1–15 (NS1-P1) B-cell epitope is specifically implicated
  • Antibodies not absorbable by purified recombinant NS1 also exist → additional non-NS1 epitopes or polyclonal B cell activation also contribute

Platelet recovery vs. persistent autoantibodies:

  • Platelet counts returned to normal range in convalescence (Table I), yet anti-platelet IgM was still significantly elevated
  • Proposed mechanism: in acute phase, platelets expressing specific surface molecules are lysed; newly generated platelets in convalescence express these molecules at lower levels, allowing platelet counts to recover despite ongoing autoantibody presence

Methods Used

  • IgM-IgG Serology ELISA (anti-NS1 IgG confirmed in sera)
  • Flow cytometric anti-platelet antibody detection (FITC-anti-human IgM/IgG secondaries, FACScan)
  • Platelet lysis assay (LDH cytotoxicity assay with exogenous complement)
  • Platelet aggregation assay (automated aggregometer, ADP stimulation)
  • RT-PCR (DENV-3 confirmation in select patients: Patients 2 and 7)

Entities Mentioned

Concepts Addressed

Relevance & Notes

Lin2001 is the chronological and evidentiary origin of the NS1 molecular mimicry → thrombocytopenia mechanism. The subsequent papers by the same group (Lin2006 - Autoimmune Pathogenesis in Dengue Virus Infection, Lin2011 - Molecular Mimicry Virus Host Dengue Pathogenesis, Wan2012 - Autoimmunity in Dengue Pathogenesis) all build on this foundation. The existing wiki pages attribute the IgM anti-platelet finding to Lin2006, which should be updated to credit Lin2001 as the original source, with Lin2006 as the study that confirmed and extended the mechanism (NS1 absorption experiments, endothelial effects, molecular target identification).

The two findings that the later NCKU papers do not foreground — and that are therefore under-represented in the existing wiki — are:

  1. Aggregation inhibition does not track severity. The lysis (complement-mediated via IgM) correlates with DHF/DSS severity; the aggregation inhibition does not. The wiki currently conflates these as a uniform anti-platelet autoimmune effect. They have different mechanistic implications: lysis explains thrombocytopenia in severe disease; aggregation inhibition may be a bystander or separate phenotype not driving severity.
  2. Primary-infection DHF/DSS with IgM anti-platelet Abs. The ADE narrative specifically requires prior dengue for the “wrong” IgG to be present. IgM anti-platelet production requires no prior exposure — it can arise in primary infection, potentially explaining the subset of patients who develop DHF/DSS without a secondary infection history.

Limitations:

  • Very small sample: 5 DF, 4 DHF/DSS patients
  • Anti-platelet IgM levels not correlated with DHF/DSS grade within the DHF/DSS group (likely underpowered)
  • The molecular target(s) on the platelet surface shared with NS1 are not identified in this paper (later addressed by Lin2011: PDI, vimentin, ATP synthase β, HSP60)
  • One patient (DSS, Patient 6) died on day 25; only acute and convalescent sera available for this patient; their exclusion from the later stage analysis makes the kinetic curve incomplete for the most severe outcome

Questions Raised

  • If anti-platelet IgM is present and functional in primary infection, why does primary dengue rarely progress to DHF/DSS? What additional factor (viral load, NS1 titre, complement competence) determines whether anti-platelet IgM levels reach the threshold for clinical thrombocytopenia?
  • The platelet surface molecules recognised by dengue patient IgM are only partially absorbed by recombinant NS1 — what non-NS1 dengue antigens drive the remaining IgM platelet cross-reactivity?
  • Does the “newly generated platelets express target molecules at lower levels” hypothesis (proposed to explain why platelet counts recover while IgM persists) have direct experimental support — i.e., do platelets from dengue convalescents bind less patient IgM than platelets from healthy donors?
  • What drives the convalescent-phase increase in platelet aggregation inhibition relative to acute? If IgM binding decreases over time (as the flow cytometry data show), why does aggregation inhibition increase?

Graph View

Backlinks